News items for the in vitro diagnostics industry for the week of Jan. 13, 2020.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
Get the latest news from Biocept, Caris Life Sciences, PerkinElmer, Inform Diagnostics, CompuNet Clinical Labs, and Drawbridge Health for the week of 7/26/19.
Senators said they'll narrow the draft bill containing changes to US patent law before submitting it to the Senate Judiciary Committee in July.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.
Get the latest news from Danaher, HTG Molecular, Bruker, Myriad Genetics, Beckton Dickinson, RenalytixAI, Caris Life Sciences, and Oxford BioDynamics for the week of 5/3/19.
NanoString said this week that it closed its previously announced underwritten public offering of 5.2 million shares of its common stock at $23 per share.